CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464600503
- Phone
- 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $10,951,125
- in 9 filings, $8.0M under 10b5-1 plans
Net −$10,951,125. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Cohen Joshua B −$4.0M Co-Chief Executive Officer sold 4% of stake
- Klee Justin B. −$4.0M Co-Chief Executive Officer sold 4% of stake
- FRATES JAMES M −$1.6M Chief Financial Officer sold 18% of stake
- MILNE GEORGE M JR −$831K Director sold 4% of stake
- Bedrosian Camille L −$325K Chief Medical Officer sold 3% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-10 | FRATES JAMES M Chief Financial Officer | Option exercise 10b5-1 | +20,000 | $6.88 | $138K | 253,625 |
| 2026-11-10 | FRATES JAMES M Chief Financial Officer | Sale 10b5-1 | −12,800 | $30.32 | $388K | 240,825 |
| 2026-11-10 | FRATES JAMES M Chief Financial Officer | Sale 10b5-1 | −7,200 | $30.97 | $223K | 233,625 |
| 2026-11-10 | FRATES JAMES M Chief Financial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −20,000 | 323,835 | ||
| 2026-11-09 | FRATES JAMES M Chief Financial Officer | Option exercise 10b5-1 | +20,000 | $6.88 | $138K | 253,625 |
| 2026-11-09 | FRATES JAMES M Chief Financial Officer | Sale 10b5-1 | −7,700 | $29.39 | $226K | 245,925 |
| 2026-11-09 | FRATES JAMES M Chief Financial Officer | Sale 10b5-1 | −12,300 | $30.11 | $370K | 233,625 |
| 2026-11-09 | FRATES JAMES M Chief Financial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −20,000 | 343,835 | ||
| 2026-09-10 | FRATES JAMES M Chief Financial Officer | Sale | −9,768 | $32.27 | $315K | 234,667 |
| 2026-09-10 | FRATES JAMES M Chief Financial Officer | Sale | −1,042 | $33.23 | $35K | 233,625 |
| 2026-08-18 | FRATES JAMES M Chief Financial Officer | Grant or award | +22,807 | 244,435 | ||
| 2026-03-05 | FRATES JAMES M Chief Financial Officer | Grant or award | +95,990 | 261,628 | ||
| 2026-03-05 | FRATES JAMES M Chief Financial Officer | Grant or award · Stock Option (right to buy) | +143,985 | 143,985 | ||
| 2026-03-02 | FRATES JAMES M Chief Financial Officer | Sale | −7,909 | $14.52 | $115K | 165,638 |
| 2026-02-02 | FRATES JAMES M Chief Financial Officer | Sale | −3,557 | $14.65 | $52K | 173,547 |
| 2026-01-06 | FRATES JAMES M Chief Financial Officer | Sale | −3,326 | $11.11 | $37K | 177,104 |
| 2025-09-30 | FRATES JAMES M Chief Financial Officer | Sale | −10,558 | $14.65 | $155K | 280,430 |
| 2025-03-31 | FRATES JAMES M Chief Financial Officer | Sale | −10,896 | $3.47 | $38K | 290,988 |
| 2025-03-06 | FRATES JAMES M Chief Financial Officer | Grant or award | +68,420 | 301,884 | ||
| 2025-03-06 | FRATES JAMES M Chief Financial Officer | Grant or award · Stock Option (right to buy) | +102,630 | 102,630 |
Page 1 of 3 · 55 trades